98%
921
2 minutes
20
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.injury.2025.112200 | DOI Listing |
Neuropsychopharmacol Rep
September 2025
Department of Behavioral Medicine, National Institute of Mental Health, National Center of Neurology and Psychiatry, Kodaira, Japan.
Masataka et al.'s cannabis gateway study misrepresents the 43.8% probability of cannabis users transitioning to illegal drugs as "rare," and misuses regression via the Table 2 Fallacy.
View Article and Find Full Text PDFAm J Emerg Med
September 2025
Department of Emergency Medicine, University of Virginia, Charlottesville, VA, USA. Electronic address:
J Robot Surg
September 2025
ORSI Academy, Melle, Belgium.
This Letter to the Editor responds to the recent publication by Patel et al. (J Robot Surg. Jul 11;19(1):370, 2025), which outlines a framework and recommendations for telesurgery.
View Article and Find Full Text PDFJ Med Internet Res
September 2025
Institute for Better Health, Trillium Health Partners, Mississauga, ON, Canada.
Background: Emerging adults living with type 1 diabetes (T1D) need targeted support to equip them with the knowledge and motivation required for self-management, particularly as they transition from pediatric to adult care. While multicomponent digital health interventions have shown promise in addressing their multifaceted needs, traditional effectiveness studies provide little, if any, insights into which components work effectively, how they function, and for whom.
Objective: This study aims to explore the implementation of a multicomponent, text message-based digital intervention (Keeping in Touch; KiT) to provide early insights into which components may shape participants' transition experiences and how.
Am J Hematol
September 2025
Department of Pediatric Hematology/Oncology, Cell and Gene Therapy, IRCCS Bambino Gesù Children's Hospital, Rome, Italy.
UBTF-TD has been reported in a significant percentage of childhood MDS-EB and has been associated with inferior survival compared to that of patients with the wild-type gene. We treated three consecutive pediatric patients affected by UBTF-TD MDS-EB with venetoclax and azacitidine (ven/aza) in combination as 28-day cycles on a compassionate use basis three consecutive pediatric patients affected by UBTF-TD MDS-EB as a bridge to allogeneic HSCT. Treatment with ven/aza was well-tolerated, and all patients responded to the ven/aza course, achieving CR with flow-cytometry negativity.
View Article and Find Full Text PDF